Clinical neurological involvement at various times throughout the illness was recorded in 52% of 122 patients seen in central London who died from acquired immunodeficiency syndrome (AIDS). Various metabolic encephalopathies, dementias, focal encephalopathies, retinopathies and peripheral nerve pathology were the most frequent manifestations. Seven of 9 patients with a neurological presentation had no other major systemic illness. The median time from diagnosis of AIDS to death was 9 months and from onset of neurological symptoms to death 4 months. Human immunodeficiency virus dementia, central nervous system opportunistic infections, presence of Kaposi sarcoma, neurological presentations and minor symptoms were not associated with major change in survival time.
Introduction
Neurological involvement in the acquired immunodeficiency syndrome (AIDS) has been described in large clinical1-6 and neuropathological7 -10 series, mainly from the USA. There is no published neurological series from the United Kingdom and in the available clinical series the incidence of neurological involvement has not been determined in relation to a defined end point. We present our experience on the nature, incidence and natural history of neurological involvement in 122 patients with AIDS seen in Central London, throughout the length of their illness. This sample represents 20% of the total number of patients with AIDS who had died in the United Kingdom by 31 September 1987.11 Methods [HIV] positive result), general medical and neurological manifestations.
The date of diagnosis of AIDS was taken in accordance with the Communicable Diseases Center guidelines. 12 The date of onset of neurological symptoms was taken from the recorded history. For The diagnosis was established by CT scan and response to treatment (n = 3), biopsy or autopsy (n = 2).
The cases of primary central nervous system (CNS) lymphoma were confirmed by biopsy (n = 2) or autopsy (n = 1). Combined CMV and HIV encephalitis was confirmed pathologically in 2 patients. These last 2 and 2 with primary CNS lymphoma presented with brain stem syndromes. Another case with CNS lymphoma and one with pathologically confirmed progressive multifocal leukoencephalopathy (PML) and multinucleated giant cells both presented with unilateral hemisphere signs.
The cause of the focal encephalopathy was uncertain in 4 patients; one presented with clinical and CT scan features of recent cerebral infarction, 1 died from acute intracranial hypertension and 2 had low density lesions in one hemisphere (one of them also in the brain stem) on CT scanning which were of uncertain nature.
Meningitis All 5 cases with a clinical presentation of meningitis were diagnosed by cerebrospinal fluid (CSF) examination (Table I) During the course of their illness 16 patients had minor or unrelated neurological complaints. Nine cases complained of headache, 4 were non-specific, 4 were related to fever and 1 was diagnosed as migraine; 5 had CT scans, of which 4 were normal and 1 showed mild atrophy. CSF was examined in 4, two had raised protein but the results were otherwise normal. The other minor complaints were (1 patient each) paraesthesiae, meralgia paraesthethica, weakness, hysterical fugue, depression, loss of memory (minor). The neurological complaints were exclusively minor in 5/64 patients (8%).
Neurological presentations The neurological manifestations fulfilled or antedated the formal diagnostic criteria for AIDS12 in 9 patients who were HIV antibody positive or had AIDS-related complex.
These were 2 meningitis (tuberculosis, cryptococcal), 2 HIV encephalopathies, and visual failure (CMV retinitis), acute myelopathy (viral), PML, vasculitis with chronic basal meningitis and primary CNS lymphoma (1 each).
Associated general medical manifestations
The following were seen in 57 cases: Pneumocystis carinii pneumonia 60 
Prognosis
The median time from diagnosis of AIDS to death was 9 months (range 0.1-42 months). The median time from onset of neurological symptoms to death was 4 months (range 0-22 months). The survival function from the time of diagnosis of AIDS in neurological patients and in 2 subgroups is given in Figure 1 . The subgroup with CNS opportunistic infections (n=22) showed no significant difference in time from AIDS to death when compared to those without (n=41) (P=0.55) although their median time from onset of neurology to death was 2 months longer (P=0.05). The median and range for time from diagnosis of AIDS to death and from onset of neurology to death for various diagnostic categories appear in Table I . In those with a neurological presentation (n=9) the median time to death of 4 months (range 1-22) was not significantly different to those with other presentations (P=0.13).
A longer median time from AIDS to death was seen in neurological patients with a diagnosis of HIV dementia (P=0.056) and in those with Kaposi sarcoma (Figure 2) . However, the median time from onset of neurological symptoms to death was not significantly different from the rest for the first (P<0.08) or second (Figure 2) subgroups.
Eighteen cases lived longer than 6 months from onset of neurological symptoms; 3 had treatable CNS infections (cryptococcal and tuberculous meningitis and toxoplasmosis), 2 had the AIDS dementia complex and myelopathy, 2 had CMV retinitis and 1 a primary CNS lymphoma. The remainder had unrelated symptoms (n =7) or seizures of unknown origin (n=3).
In 5 cases who had exclusively minor neurological symptoms the median time from AIDS to death was 4 months (range 2-9), and from onset of neurological symptoms to death 1 month (range [1] [2] [3] [4] .
Six patients received zidovudine and died 5, 2 and 1 (n = 4) months after it was started.
There was no significant difference in mean age in the various subgroups considered above. 
Discussion
This sample of 122 patients represents nearly 30% of the total number of AIDS cases reported dead in the four London National Health Service regions by the 31 September 1987. Only 6 of them received zidovudine during life. The findings are therefore representative of the natural history of neurological involvement in AIDS as seen in Central London.
The 52% incidence of neurological involvement detected in this group is higher than other large clinical series,16 probably because we considered all recorded neurological findings throughout the illness. It is lower than the 70-80% incidence quoted in neuropathological series7'8'9 probably for several reasons. Firstly, the neurological symptoms may be minor in relation to major systemic illness and may be under reported, especially minor cognitive impairments. 17 Our retrospective series included only patients with AIDS who had died by a specified date. Cases with longer survivals would have been excluded. However, the prognosis in this group was poor irrespective of the cause of the neurological involvement and whether it was treatable or not. This is consistent with one series of cerebral toxoplasmosis19 which had a median survival of 3.75 months (range 8 days-12 months) in 18 treated cases and with another of 24 cases of cryptococcal disease20 with 5 survivors for periods of 11 weeks to 9 months. In these series, as in our cases, successful treatment of neurological opportunistic infection was often followed soon by some other fatal systemic manifestation. Our longest survivals after treating cerebral toxoplasmosis, primary CNS lymphoma and cryptococcal and tuberculous meningitis were 12, 7, 10 and 20 months respectively (Table I ). The time from AIDS to death in cases with toxoplasmosis, meningitis and primary CNS lymphoma was not significantly different from that of the rest of the series. The median times from AIDS to death in patients with HIV dementia and with Kaposi sarcoma and from neurology to death in those with CNS opportunistic infections were significantly longer, or nearly so, but the differences from the rest of the series were clinically trivial. Fifty per cent of metabolic encephalopathies occurred in the last 2 months of life, but duration of the disease (time from AIDS to death) in these patients was not significantly different from the rest. Interestingly, patients with exclusively minor neurological symptoms did not appear to have a better prognosis.
